Heron Therapeutics | HRTX - Current Assets


Heron Therapeutics reported $229.84M in Current Assets for its fiscal quarter ending in June of 2026.





Current Assets Change Date
ALKERMES USD 1.52B 164.26M Jun/2026
Alnylam Pharmaceuticals USD 4.62B 400.86M Jun/2026
Amarin USD 602.76M 23.26M Jun/2026
ANI Pharmaceuticals USD 825.43M 78.35M Jun/2026
Anika Therapeutics USD 99.19M 5.63M Jun/2026
Arrowhead Research USD 1.67B 168.34M Jun/2026
Eisai JPY 883.01B 121.38B Jun/2026
Emergent BioSolutions USD 679.5M 41.3M Dec/2023
GlaxoSmithKline GBP 17.56B 202M Jun/2026
Heron Therapeutics USD 229.84M 861K Jun/2026
Insmed USD 1.63B 20.75M Jun/2026
Ligand Pharmaceuticals USD 1.46B 591.7M Jun/2026
Merck USD 36.68B 1.66B Jun/2026
Nektar Therapeutics USD 589.04M 322.77M Mar/2026
Neurocrine Biosciences USD 1.64B 798.6M Jun/2026
Omeros USD 69.65M 26.53M Jun/2025
Pacira USD 615.21M 100.25M Jun/2026
Regeneron Pharmaceuticals USD 18.45B 236.8M Jun/2026
Roche Holding CHF 35.44B 3.29B Jun/2026
Sangamo BioSciences USD 49.89M 12.3M Jun/2025
Ultragenyx Pharmaceutical USD 606M 51M Jun/2026
Veracyte USD 574.78M 52.6M Jun/2026
Vertex Pharmaceuticals USD 12.54B 813.4M Jun/2026